• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    新冠疫情視角下生物技術(shù)風(fēng)險化解與法律規(guī)制

    2021-08-17 16:22:50葛倩倩王金金
    科技與法律 2021年1期
    關(guān)鍵詞:生物技術(shù)新冠疫情法律規(guī)制

    葛倩倩 王金金

    Absract: Biotchnology risk response must be considered, before science and technology cautiously promotes the development and innovation of biotechnology for COVID-19 prevention and control, on the basis of risk prevention. The prevention and control of biosecurity threats should proceed within the law and properly handle the biotechnology risks in COVID-19 research under legal norms. The goal is to reshape the principles and attitudes for the development of biotechnology, to prevent and dissolve any ambiguity caused by the application of biotechnology, to create a suitable space for the growth of biotechnology under the rule of law, and to realize the harmonious development of biotechnology and human society under the regulation of law. The Biosecurity Law of the People's Republic of China was promulgated on October 17, 2020, improving the legal and normative system in the field of biotechnology and providing guidance for the healthy development of biotechnology. With the increasingly prominent position and the important role of biotechnology in national development systems, it is a critical legal proposition in the era of biotechnology to establish fair laws and regulations of biotechnology to achieve good governance in the field of life science, thereby establishing and protecting public welfare in the development process of biotechnology.

    Key words: biotechnology risks, risk mitigation, legal regulation, COVID-19 Pandemic

    CLC: D 912???????????????????? DC:A??????????????????????? Article ID:2096-9783(2021)01-0140-09

    1. Introduction

    The biosafety risks posed by biotechnology demonstrate the power of science and technology while showing that such technology involves huge hidden risks. The new round of the biotechnological revolution has penetrated all fields of human society and aroused the close attention of the international community. At a time when the global COVID-19 crisis requires urgent responses, the vast majority of countries and regions in the world have exposed weaknesses in their biosafety systems. In 2020, Liu Chong and Deng Wenjia point out that due to the global spread of COVID-19, the complex changes and wide application of emerging biotechnology have posed severe challenges to the system of balancing interests and risks established by traditional laws[1]. In 2019, Wang Xiaoli points out that the risk of biotechnology is the risk caused by the violation of the law of technology itself and the original intention of technology development in the process of human development and the utilization of biotechnology[2]. This risk is often characterized by great difficulty in prediction, strong economic and social relevance, and major threats to overall national security.

    Certain biomaterials, biotoxins in laboratories, potential pandemics, and introductions of invasive species into ecosystems have long been recognized as risk issues that affect public health and the environment. From bacteriology in the late 19th century, to aerobiology and virology in the mid-20th century, to biotechnology such as genetic engineering, gene editing and synthetic biology, hidden risks have always existed because of the "dual use" of technology. At the practical level, governments attach great importance to the risk of biotechnology. Countries such as America, Britain, and Australia have issued national strategies for biological safety to strengthen biological safety management at home and abroad. The overall goal is to build a comprehensive, international, biological defense system. The risk of biotechnology is also an important area of research for many institutions. The European Commission, the Royal Society, the German Research Foundation, and others have all carried out studies on biosafety, security risk assessment, and regulatory principles. In the academic world, Ghasemi and Karami (2019) point out that researchers have begun to pay attention to the ethical aspects of biotechnology issues, regarding morality and ethics as important factors affecting risk perception[3]. On the one hand, Van Wezel (2017) emphasizes the establishment of systematic risk prevention and control measures from the aspects of system, laws and regulations, ethics, and public opinion guidance[4]. On the other hand, in the era of globalization, Sandberg and Nelson (2020) point out that due to the differing regulatory approaches in different countries, most effectively managing the risks and benefits arising from the progress of gene technology requires a better understanding of the similarities and differences of the various national regulatory systems in[5]. There is a great need to strengthen global cooperation and establish multi-level prevention and protection actions. In general, in the process of studying the risks of biotechnology, scholars mainly focus on the frontier emerging fields of biotechnology and the forward-looking, pioneering, and exploratory major technologies in the field of biotechnology; they focus on the analysis of gene engineering and gene editing in the field of genetic engineering, as well as synthetic biology and other technical fields.

    Driven by the Third Technological Revolution, human society began to become what Ulrich Beck called a "risk society" in the 20th century. Technological risks represented by biological technologies such as gene editing, synthetic biology, and stem cell manipulation are rapidly rising to become the most important risks in a modern risk society. In 2006, WHO points out that lab biosafety and the narrow sense of technical biotechnology risk are two sides of the same coin, but the latter focuses on "the protection, control, and accountability of valuable biomaterials in the laboratory with the aim of preventing unauthorized access, loss, theft, abuse, transfer or intentional release"[6]. In the age of big data, Sture and Whitby (2013) point out that not only must biomaterials be well controlled, but "equal attention must be paid to information, knowledge, processes, practices, and equipment related to potentially or actually dangerous biomaterials"[7]. The major risk of biotechnology is that it is difficult to predict; has strong economic, social, and political relevance; and can greatly threaten overall national security. Problems exist: At the operational level, how do we define risks, who decides what those risks are, and how do we address them? Jasanoff and Sarewitz (2015) point out that the identification of technical risks is often made by the scientists themselves, rather than involving a broader group of stakeholders, which can lead to a rather narrow definition of the risks involved[8]. To this end, they suggest using a more inclusive and democratic approach to define and deal with risks.

    2 Risks in the Development of Biotechnology in the Context of COVID-19

    It is assumed that the COVID-19 outbreak started in Wuhan, China, in January 2020. By January 30, the number of confirmed COVID-19 cases had surpassed that of SARS in 2003. By August 27, China had reported 90,293 confirmed COVID-19 cases and 4,720 deaths. As of August 27, 2020, the disease had spread to 215 countries and regions, with more than 23 million cases and a confirmed death toll exceeding 810,000. Confirmed cases in the U.S. numbered above 5.85 million, and the U.S. cumulative death toll exceeded 1800001. Although COVID-19 is well under control in China, the force of COVID-19 is still strong in the international community. COVID-19 has brought pain to all humanity, and the epidemic is still spreading around the world, plunging the world economy into a severe recession. In the face of the COVID-19 pandemic, we need to recognize the inherent character of biotechnology, which, along with technological change and social interaction, benefits human society but also poses security threats and risks.

    2.1 Consideration of Ecosystem Security Risks

    Risk refers to the possibility or opportunity of suffering danger, loss, injury. From the perspective of safety science, risk is the possibility and consequence of a specific hazardous event. In this paper, risk refers to the harm that biotechnology may cause to human health or the ecological environment. Modern technologies, such as biotechnology, based on risk society theory, have brought human society into what Ulrich calls a "risk society", in which "productivity loses its innocence, wealth gains from technological progress and becomes increasingly the dark side of risk production." In this view, technology is not only a way to solve problems; it is also a troublemaker"[9]. The prosperity and development of biotechnology have gradually become an important force to promote the progress of human society and industrial innovation.

    Like other scientific and technological achievements, the development of biotechnology has a two-sided nature. On the one hand, it has solved many dilemmas such as food crises, environmental problems, human health issues, and energy problems for the development of humanity, and it has brought huge economic benefits. On the other hand, the development of biotechnology will inevitably produce internal and external negative effects. For example, this development can guarantee neither human health and safety nor ecological and environmental balance, as well as raising issues such as the right to know, privacy, and social ethics. In the face of the huge threat to human health brought by COVID-19, a series of diagnosis and treatment technologies and vaccine research and development have made outstanding contributions to the response to COVID-19 and the protection of human health. However, we cannot ignore the need to determine whether these diagnostic techniques and future vaccines will bring new unknown health risks.

    The most crucial goal of COVID-19 research is to prevent more people from getting the novel coronavirus, and to achieve this goal, the new vaccine research and development of China have been at the forefront of the world. The COVID-19 vaccine developed by Academician Chen Wei's team was the first, both domestically and internationally, to enter the phase I and phase II clinical trials, demonstrating the safety and immunogenicity of the vaccine. The vaccine's stage Ⅲ international clinical trial is proceeding. The vaccine uses technical intervention to form antibodies in the body that block the development of the virus and protect the body against its invasion. This process of human intervention, however, is actually the destruction of the original ecosystem; the essence of its operation is to create a new ecosystem, which can very easy to destroy the original ecosystem. Reactions, such as allergic and immunogenic reactions, can occur. Looking back at previous epidemics caused by coronaviruses, the virus mutates rapidly, and the antibodies produced by the vaccine protect against such epidemics for only three to six months. On the one hand, there is no data to support whether vaccination will bring adverse effects. On the other hand, it is not yet known whether the antibodies produced by the vaccine can resist the mutation of the virus. These risks are currently unknown.

    2.2 Consideration of Human Health Risks

    The development of biotechnology can meet the growing material and cultural needs of humankind, especially in food security, human health, energy security, and other aspects of outstanding value and significance. However, biotechnology is a double-edged sword, which needs to go through a long process to mature. Especially in the early stage of technology development, there are great safety risks in the process of the research, experimentation, and release of the results, and these risks are often uncontrollable and unknown. Many treatments have been used during the pandemic of COVID-19, and so far, the results have been good, but we do not know for sure that these treatments will not harm patients. In the fight against COVID-19, the joint research team from the Department of Life Science and Medicine and the First Affiliated Hospital of the University of Science and Technology of China (USTC) attracted much attention, and the team proposed the diagnosis and treatment plan of "Tozumab + routine treatment". The team found that interleukin-6 (IL-6) is an important pathway that induces inflammatory storms in patients with COVID-19[10]. This diagnosis and treatment scheme has been popularized in more than 20 countries worldwide and widely shared in international academic circles. However, abnormal liver function, skin damage, allergic reaction, gastrointestinal damage, infection, blood system damage, and other such adverse reactions may occur during the clinical use of Tozumab. Therefore, although Tozumab has achieved good results in the treatment of COVID-19, we should not ignore the risks that this drug brings.

    2.3 Consideration of Social Order and Ethical Risks

    The development of biotechnology will not only bring risks to ecological security, human health, resources, but also bring many ethical risks. "In the field of science and technology, which can bring great risks and disasters to mankind, the preconditions for free research have fundamentally changed dramatically" (Ulrich, 1986). Many biotechnologies set man against nature, and the course of life no longer follows the laws of nature but the will of man. The development of technology has changed the original ecological balance, which has led to many new problems. The origin of novel coronavirus has not yet been determined, but the over transformation of nature by humans must be responsible for it. Respect for social order and moral ethics is a necessary stipulation for the development of biotechnology. Otherwise, the balance between humanity and nature will be broken, and human beings will suffer bad consequences.

    3 Legal Provision of Biotechnology Safety Risks in China

    In the field of preventing the risk of infectious diseases outbreak, China's legal basis mainly includes the Emergency Response Law, the Law on the Prevention and Treatment of Infectious Diseases, the Frontier Health and Quarantine Law, and the Regulations for Emergency Response to Public Health Emergencies, which constitute the basic legal framework of China's response to public health emergencies. However, under the challenge of the epidemic, many shortcomings in the provisions of the law have been exposed. In 2020, the new Biosecurity Law included infectious diseases in the category of biosafety, which was elevated to the height of national security and provided precise legal positioning for infectious diseases. However, the authorization of local governments for emergency treatment measures still needs to be further enriched and improved. Taking the epidemic as an example, there are no clear provisions detailing the isolation of high-risk groups and whether cities can be "closed down".

    In the field of preventing the misuse and abuse of biotechnology, China issued the Regulations on the Export Control of Dual-use Biological Agents and Related Equipment and Technologies in 2002, the Measures for the Ethical Review of Biomedical Research Involving Human Beings in 2016, and the Measures for the Safety Management of Biotechnology Research and Development in 2017. These specifications aim to regulate biological technology research and development, promoting and safeguarding the healthy development of biotechnology. Biosafety risks and responsibilities are stipulated in the research and development and commercial application of biotechnology. The newly promulgated Biosecurity Law has many principle provisions on the research and development and application of biotechnology, but there should still be supplementary legislation to ensure the law's implementation. Relevant legislative guidance is an important guarantee for dealing with a major epidemic. In the early stage of the COVID-19 outbreak, due to the lack of supporting legislative guidance, researchers were not qualified to provide guidance and support on the scene of such sudden outbreak of biosafety incidents, so they could only quickly set up emergency response teams. The USTC team is one of them, and it succeeded in quickly identifying the virus and putting forward a treatment plan. With appropriate legislative guidance, such teams could have stepped in with legal guidance at the beginning of an outbreak, but the current legislation in this area is lacking.

    In the field of preventing biotechnological ecological security risks, China's legislation needs strengthening. Biotechnology ecological security risk prevention is a complex systematic project which needs a scientific, reasonable, coordinated, and powerful operation system to ensure the efficient and orderly development of ecological security management[11]. The Measures for The Safety Management of Genetic Engineering issued by the former State Science and Technology Commission (now the Ministry of Science and Technology) in 1993 was China's first legal norm in the field of biotechnology safety; it regulates all the behaviors related to gene research in China. In 2001, in accordance with the relevant provisions of the Cartagena Protocol on Biosafety, the Chinese State Council promulgated the Regulations on the Safety management of Agricultural GMOs, which is the first administrative regulation regulating the safety of biotechnology in China. In China, ecological security risk prevention norms of biotechnology mainly focus on the field of gene technology. In addition, no other normative documents regulate ecological security risks in China[12]. At present, China lacks a complete legislation system for the prevention of biotechnological ecological security risks, especially for such biosafety incidents as COVID-19; such legislation is urgently needed.

    4 Experiences of the Major Countries in the Legal Regulation of Biotechnology Risks

    With the increasing technological risks in major biosecurity fields, such as the study of epidemics, technological optimism has been questioned. Interested parties wonder whether the law should unconditionally protect the freedom of scientific research; the question of whether the country should not put any scientific issues off-limits has become a new issue that needs to be urgently addressed. The freedom of scientific research is not absolute; it should be constrained by both nature and ethics, so it is necessary to use the legal system to set restricted areas for scientific issues[13]. The typical biosafety legislation of various countries is of great significance, especially considering the experience of big countries in the legal regulation of biosafety, R&D, and application of biotechnology.

    4.1 The United States: Adopting the Principle of Substantive Equivalence to Encourage the Development of Technology

    In the field of biosafety management, the United States advocates the principle of substantive equivalence. This principle refers to the identification of a traditional transaction without the possibility of determining whether there is a risk for it. The United States advocates the freedom of scientific research. When the safety risks of biotechnology have not been confirmed by science, the United States government will not impose very strict management and restrictions on scientific research of biotechnology.

    In the field of biotechnology safety regulation, the United States has established a series of technical evaluation standards for the safety, R&D, application, and other facets of biotechnology, mainly through relevant experience in the history of technology development. For the development of cutting-edge technologies, including biotechnology, a relatively relaxed and encouraging policy has been adopted. The green light has been given to many biotechnology projects, including synthetic biotechnology, on the premise that the source of risk can be controlled, so there is no resistance to their development.

    In 1976, the National Institutes of Health (NIH) of the United States formulated the Recombinant Gene Molecular Research Guidelines, which stipulated the safety management of transgenic technology and the responsibility of the experimenter, also setting a precedent for the legal protection of biotechnology safety. In 1986, the United States government authorized the Department of Agriculture, Environmental Protection Agency, Food and Drug Administration, Occupational Safety and Health Administration, and National Institutes of Health to coordinate the management of safe progress in biotechnology. With the Recombinant Gene Molecular Research Guidelines as the main framework, the United States has successively issued the Manual for Biological Safety in Microbiology and Biomedical Laboratories; the Preservation, Use and Transfer of Selective Agents and Toxins; the Development Policy Guidelines and Suggestions on the Management and Supervision and Review Mechanism of Potential Pandemic Pathogens; the Standard Operating Procedures for Biological Safety in Laboratories of the United States, and the Training Guidelines for Standard Operating Procedures for Microbiology Laboratories Personnel; these documents all regulate biological operations. Along with the Concern on Biosafety and Biotech Dual-use Research, the US Government's Regulatory Policy on Biosafety and Biotechnology Dual-use Research, these norms constitute the legal and normative system in the field of biotechnology in the United States[14]. The National Biodefense Strategy, released in 2018 included the intentional misuse of biotechnology in the list of national biosecurity threats for the United States and tested the implementation of the national biosecurity strategy. The National Health Security Strategy Implementation Plan 2019-2022, released in the same year, emphasized the need to strengthen the management of microbiological agents and actively respond to biosecurity threats. It has to be said that the United States has made a series of explorations in biotechnology risk prevention and control.

    4.2 Europe: Adopt the Precautionary Principle to Treat Technical Risks Prudently

    Compared to the U.S., which has encouraged the development of biotechnology, the Europeans are more conservative. Europe has adopted the precautionary principle in the field of biotechnology; that is, measures to prevent the occurrence of hazards are not be taken on the grounds of the uncertainty of biotechnology. According to the principle of risk prevention, biotechnology involves great uncertainty, and once the risk occurs, its damage consequences are often incalculable. Therefore, even if the current scientific evidence proves that the damage might not happen, certain preventive measures should be taken. Most European countries insist that biotechnology research that poses safety risks is monitored with caution.

    The regulation of biotechnology is stricter in European countries than in the U.S., especially for biotechnology and the products derived from it, which are often regulated by stringent legislation. The EU has formulated ten regulations, six directives, and six resolutions in the field of biotechnology, such as gene technology[15]. All the regulations have legal effect in each Member State, and each Member State needs to improve its national legislation within the specified time under the directive's requirements.

    To facilitate the management of gene-editing technology, Germany has successively issued the Recombination Gene Molecular Experiment Criteria, Gene Technology Law, Gene Technology Safety Regulations, and Embryo Protection Law. Germany's Biotechnology Law came into effect formally in 1990. The law controls the development and application of biotechnology, delineates the regulatory authority for biotechnology, and stipulates the liability for compensation for damage caused by biotechnology and products. The law was designed to prevent the risks that may be brought by biotechnology and products. In the past two years, Britain issued a series of strategies related to the field of biotechnology, including the National Industrial Biotechnology Strategy 2030, 2030 National Biological Economic Strategy, and Solve the Antimicrobial Drug Resistance in 2019-2024: The British National Action Plan for 5 Years. Britain proposed to make full use of biological technology to improve the structure of its national economy but specified that attention should be paid to limiting biological technology that may bring huge risks.

    4.3 China: Managing the Balance Between Risk Prevention and Prudent Development of Biotechnology

    Article 2 of China's Biosecurity Law mandates adherence to the principles of people-orientation, risk prevention, classified management, and coordination. While encouraging the innovation and development of biotechnology, the paper proposes to follow the principles of risk prevention and cautious development. Biotechnology is often closely related to the development of human society. Once risks are translated into reality, the consequences are often very serious and irreversible. Therefore, it is necessary to establish the principle of risk prevention. The principle of prudent development seeks a balance between the security of biotechnology and the development of biotechnology; this principle provides theoretical guidance for the construction of a legal system to ensure the security of biotechnology, and thus lays a foundation for the realization of justice and order. Adhering to the principles of risk prevention and prudent development is a path that must be followed by the rule of law to ensure the healthy development of biotechnology in China[16].

    At present, the legislation on biotechnology safety in China is composed of more than 90 laws, regulations, rules, and normative documents, dominated by the Biosecurity Law. The Biosecurity Law is a fundamental and comprehensive law in the field of biotechnology. Most of the regulations in the field of biotechnology other than biosecurity Law are administrative regulations formulated by the competent authorities of the industry. Although these other protocols provide a way to promote biotechnology safety in specific fields, some of them are old and cannot meet the needs of the current development of biotechnology. So far, China's current regulations and norms in the field of biotechnology have played a certain role in protecting the development of biotechnology[17]. However, to ensure the sustainable and healthy development of biotechnology, there is still a long way to go for the rule of law based on risk prevention and prudent development.

    5 Improvement of Legal Regulations on Major Risks of Biotechnology

    Apart from the Biosecurity Law, the current legislation in the field of biotechnology enforced at a low level of government and was promulgated too long ago to meet the challenges brought by the rapid development of biotechnology. After the outbreak of COVID-19, attention was once again attached to the topic of biosafety, and since biosafety is related to national security, the national Biosecurity Law came into being, which is bound to play a major guiding role in the development of biotechnology. We believe that under the legal norm system in the field of biotechnology dominated by the Biosecurity Law, the legal regulation of biotechnology can be improved in the following aspects.

    5.1 Formulation of Laws Supporting the Biosecurity Law

    From the perspective of legislative orientation, the Biosecurity Law is more like the basic law with broad regulatory scope and strong principles. From the perspective of content, the Biosecurity Law mainly provides the general provisions for biosafety. The promulgation of the Biosecurity Law has provided guidance for the healthy development of biotechnology, but biotechnology is complex and needs to be regulated by complete and detailed legal provisions. It is very important to formulate special laws to assist the better implementation of the Biosecurity Law. Taking the safety of human genetic resources and biological resources as an example, the Biosecurity Law stipulates that the collection, preservation, utilization, and provision of human genetic resources in China shall protect human health and safeguard national security and social and public interests[18]. The Biosecurity Law considers exact definition: the interpretation of human genetic resources is narrowed to human genetic resources with or without modification, which covers modified genetic resources such as those produced by transgenic technology, gene editing techniques, and synthetic biology technology.

    5.2 Legislation on the Public Compensation Mechanism

    At present, China has no relevant provisions on public compensation in any biotechnology-related legal norm, but the public compensation system is an important link in dealing with public safety accidents, so inevitably, the government must formalize and enact a comprehensive public system. Take this epidemic as an example, COVID-19 has not only harmed people's health but also caused serious economic losses and even economic stagnation. Biotechnology safety accidents typically cause economic losses within a certain range. Some of the damage is caused by the government's administrative action, and this loss cannot be compensated through the tort liability system. The biotechnology legislation on the public compensation system should be clear about dealing with such economic loss if it is caused by biotechnology safety accidents. As for public compensation funds, they may be incorporated into the government fiscal budget, or special security funds may be set up by governments at all levels as a source of compensation. As for the standard of compensation, we can refer to the local price level and the actual loss to give careful consideration. In addition, enterprises can be given preferential tax policies, and citizens can be given preferential policies.

    5.3 Legislation on the Professional Ethics of Scientific Researchers

    Many risks induced in the development and application of biotechnology are both ethical and legal. The inclusiveness between ethics and law provides feasibility for establishing a legal framework for the professional ethics of scientific researchers. There are few related laws at present regulating researchers in China, China lacks science and technology progress law, administrative rules, and other regulatory documents for most kinds of scientific research personnel; systematic, consistent rules for the scope of their duties are needed to coordinate such research efforts[19]. In addition, China's relevant laws and regulations on scientific researchers are dominated by the idea of encouraging the development of science and technology. Although there are provisions relating to legal responsibility, there is a lack of content specifically addressing legal responsibility, making the legal norms lack operability.

    5.4 Strengthening of the Legal Principle of Extensive International Cooperation

    Biotechnology risks are global in character. Guided by the vision of building an international community with a shared future for humanity, countries around the world are working to develop and improve the global rules of co-governance of biotechnology risks. China's newly promulgated Biosecurity Law incorporates into its legal principles the concept of a community with a shared future for humankind, plans extensive international cooperation on biotechnology security using this concept, and seeks to build a strategic consensus for the development of emerging biotechnology in the international community. In the global fight against the COVID-19 pandemic, China should actively advocate a global biotech safety net, form a truly feasible international agreement, and try hard to put it into practice. China should actively participate in formulating or amending international biotechnology rules and standards among the surrounding countries, regions, and regional organizations. Efforts should be made to popularize advanced ideas and to express the interests of all parties.

    6 Conclusion

    Both the significant innovation progress and the emerging risk threat of biotechnology will become hot spots of academic exploration and focuses of public opinion. Law is the prerequisite and the foundation to ensure that biotechnology development advances on the track of promoting scientific and technological innovation and maintaining social welfare. Chinese current legislation on biotechnology are few and dated and need to be improved. The establishment of a scientific management system adapted to the actual needs of biotechnology and the effective connection with the existing legislation will provide a more solid legal basis for strengthening the legal system construction of biotechnology safety and safeguarding national security.

    It can be seen from the above discussion that attention should be paid to the risks of biotechnology in order to improve the legislation in the field of biotechnology in China and guarantee the development of technology on the basis of current laws and by referring to advanced foreign legislation.

    References:

    [1] Liu Chong, Deng Menja. The Impact of Emerging Biotechnology Development on Great Power Competition and Global Governance[J]. Modern International Relations, 2020(6): 1-10.

    [2] Wang Xiaoli. Biosafety Era: New Biosafety Transformation and National Security Governance[J]. International Security Studies, 2020, 38(4): 109-135.

    [3] Ghasemi, S., Ahmadvand, M., Karami, E. et al. Social Risk Perceptions of Genetically Modified Foods of Engineers in Training: Application of a Comprehensive Risk Model[J]. Science and Engineering Ethics, 2019: 25.

    [4] Van Wezel A P, Van Lente H, Van d S J M, et al. Risk analysis and Technology Assessment in Support of Technology Development: Putting Responsible Innovation in Practice in a Case Study for Nanotechnology[J]. Integrated Environmental Assessment and Management, 2017: 9-16.

    [5] Sandberg Anders,Nelson Cassidy. Who Should We Fear More: Biohackers, Disgruntled Postdocs, or Bad Governments? A Simple Risk Chain Model of Biorisk.[J]. Health Security, 2020, 18(3): 9.

    [6] Health Organization (WHO). (2006). Biorisk Management: Laboratory Biosecurity Guidance. Retrieved from http://www.who.int/ihr/publications/WHO_CDS_EPR_2006_6.

    [7] Sture, J., Whitby, S., & Perkins, D. Biosafety, Biosecurity and Internationally Mandated Regulatory Regimes: Compliance Mechanisms for Education and Global Health Security[J]. Medicine, Conflict and Survival, 2013, 29(4), 289-321.

    [8] Jasanoff, S., Hurlbut, J. B., & Saha, K. CRISPR Democracy: Gene Editing and the Need for Inclusive Deliberation. Issues in Science and Technology.? 2015,32.

    [9] Zhang Zhiyu, Liu Xiaobing. On the Legal Prevention of Ecological Security Risks of Biotechnology[J]. China's Environmental Rule of Law, 2014(2): 1-24.

    [10] Wang Tao. Analysis of the Mechanism of Action and Safety Risk of COVID-19 Immunotherapy Drug Tozumab[J]. Pharmacovigilance in China, 2020, 17(5): 257-260.

    [11] Zhang Hui. Legislation Appeal of Biosafety[J]. Modern Law, 2008(6): 147-156.

    [12] Wang Kang. Legislation Orientation of Biosecurity Law and Risk Control of Gene Technology[J]. Journal of Beijing University of Aeronautics and Astronautics (Social Science Edition), 2019, 32(5): 27-29.

    [13] Ding Guomin, Guo Shijie. The Value Conflict and Solution of Biosafety Legislation[J]. Journal of Shanxi University (Philosophy and Social Sciences Edition), 2020, 43(4): 89-95.

    [14] Du Lu. Brief Discussion on Foreign Biosafety Legislation[J]. Legal System and Economy (Late Edition), 2014(5): 4-5.

    [15] Xue Yang, Yu Hanzhi. Security Threats of the Development of Frontier Biotechnology: Countermeasures and Prospects[J]. International Security Studies,2020,38(4): 136-156.

    [16] Yu Wenxuan. Rule of Law Principle and Realization Path of Biosafety Guarantee[J]. Exploration and Controversy, 2020(4): 160-166.

    [17] Liu Xuxia. Biosafety Law Should Highlight The Safety Prevention of Biotechnology[J]. Journal of Beijing University of Aeronautics and Astronautics (Social Science Edition), 2019, 32: 25-26.

    [18] Yang J W. Construction of Collaborative Management Mode of Gene Risk under the Background of National Biosafety Risk Prevention and Control System[J]. Journal of China University of Political Science and Law, 2020(3): 149-159.

    [19] Fu Qian. Research on the Legalization of Professional Ethics of Contemporary Chinese Researchers[D]. Northeastern University, 2014: 11-13.

    新冠疫情視角下生物技術(shù)風(fēng)險化解與法律規(guī)制

    葛倩倩,王金金*

    (中國科學(xué)技術(shù)大學(xué)? 公共事務(wù)學(xué)院,合肥 230026)

    摘??? 要:生物技術(shù)風(fēng)險應(yīng)對必須走到科技的前面去,在風(fēng)險預(yù)防的基礎(chǔ)上審慎推動新冠疫情防治生物技術(shù)的發(fā)展創(chuàng)新;對生物安全威脅的防控更應(yīng)走到法律的內(nèi)部去,在法律規(guī)范下妥善處置新冠疫情中的生物技術(shù)風(fēng)險。重塑發(fā)展生物技術(shù)的原則和態(tài)度,防范和化解生物技術(shù)應(yīng)用產(chǎn)生的陰霾,創(chuàng)設(shè)適宜的生物技術(shù)生長的法治空間,實現(xiàn)在法律規(guī)制下的生物技術(shù)與人類社會的協(xié)調(diào)向善發(fā)展。2020年10月17日《中華人民共和國生物安全法》頒布,完善了生物技術(shù)領(lǐng)域法律規(guī)范體系,為生物技術(shù)健康發(fā)展提供導(dǎo)向。隨著生物技術(shù)在國家發(fā)展體系中的地位日益突出、作用日益重要,探索規(guī)范生物技術(shù)之良法以求生命科學(xué)領(lǐng)域之善治,以求在生物技術(shù)發(fā)展進程中確立和保障社會公益,是生物科技時代的重大法治命題。

    關(guān)鍵詞:生物技術(shù);風(fēng)險化解;新冠疫情;法律規(guī)制

    猜你喜歡
    生物技術(shù)新冠疫情法律規(guī)制
    新冠疫情視閾下感悟“四個自信”國家共識
    “心理成長任務(wù)包”助力學(xué)生安度疫情
    關(guān)于疫情對地區(qū)經(jīng)濟金融影響情況的調(diào)研
    新冠疫情對縣域脫貧產(chǎn)業(yè)發(fā)展的影響及地方金融支持的建議
    生物技術(shù)在環(huán)保工程中的應(yīng)用
    淺析生物技術(shù)在水污染治理中的應(yīng)用
    高職院校生物技術(shù)專業(yè)《生物化學(xué)》教學(xué)現(xiàn)狀與對策
    科技視界(2016年26期)2016-12-17 20:36:02
    淺析林業(yè)育種和生物技術(shù)的應(yīng)用
    商業(yè)預(yù)付卡經(jīng)營行為的法律規(guī)制
    我國網(wǎng)絡(luò)經(jīng)濟中不正當競爭行為的法律規(guī)制
    404 Not Found

    404 Not Found


    nginx
    精品人妻一区二区三区麻豆| 亚洲人成电影观看| 欧美bdsm另类| 国产人伦9x9x在线观看 | 99re6热这里在线精品视频| 人体艺术视频欧美日本| 精品国产一区二区久久| 国产成人av激情在线播放| 欧美国产精品va在线观看不卡| 超碰97精品在线观看| 精品视频人人做人人爽| 大话2 男鬼变身卡| 国产男人的电影天堂91| 中文乱码字字幕精品一区二区三区| av线在线观看网站| 成人免费观看视频高清| 搡女人真爽免费视频火全软件| 久久99热这里只频精品6学生| 久久人人爽人人片av| 青春草视频在线免费观看| 成年美女黄网站色视频大全免费| 各种免费的搞黄视频| 大片免费播放器 马上看| 国产精品久久久久久精品古装| 欧美激情 高清一区二区三区| 美女大奶头黄色视频| 亚洲精品乱久久久久久| 99久国产av精品国产电影| 亚洲av在线观看美女高潮| 国产欧美亚洲国产| 亚洲美女视频黄频| 人妻人人澡人人爽人人| tube8黄色片| 久久国产精品大桥未久av| 久久精品国产自在天天线| 综合色丁香网| 晚上一个人看的免费电影| 国产精品二区激情视频| av福利片在线| 久久热在线av| 精品国产超薄肉色丝袜足j| 一区福利在线观看| 亚洲av国产av综合av卡| 青青草视频在线视频观看| 青春草国产在线视频| 热99久久久久精品小说推荐| 久久精品亚洲av国产电影网| 亚洲精品久久午夜乱码| 成年av动漫网址| 大香蕉久久网| 桃花免费在线播放| 最近手机中文字幕大全| 成年女人在线观看亚洲视频| 美女大奶头黄色视频| 国产亚洲午夜精品一区二区久久| 秋霞在线观看毛片| 中文字幕人妻丝袜一区二区 | 中文字幕最新亚洲高清| 久久久久久免费高清国产稀缺| 18禁国产床啪视频网站| 久久精品亚洲av国产电影网| 久久精品久久精品一区二区三区| 午夜精品国产一区二区电影| www.av在线官网国产| 国产一区二区三区av在线| 国产一区二区 视频在线| 在线免费观看不下载黄p国产| 两个人免费观看高清视频| 久久精品国产亚洲av高清一级| 一本色道久久久久久精品综合| 精品卡一卡二卡四卡免费| 国产在线一区二区三区精| 亚洲,欧美,日韩| 制服诱惑二区| 精品少妇内射三级| 欧美av亚洲av综合av国产av | 各种免费的搞黄视频| 丰满少妇做爰视频| 久久久国产欧美日韩av| 男女免费视频国产| 中文字幕最新亚洲高清| 欧美成人精品欧美一级黄| 不卡视频在线观看欧美| 久久精品国产自在天天线| av卡一久久| 老熟女久久久| 伊人亚洲综合成人网| 日本猛色少妇xxxxx猛交久久| 亚洲欧美中文字幕日韩二区| 午夜福利,免费看| 男人操女人黄网站| 午夜老司机福利剧场| 久久精品国产鲁丝片午夜精品| 免费高清在线观看日韩| 又粗又硬又长又爽又黄的视频| 国产精品熟女久久久久浪| 成年女人在线观看亚洲视频| 亚洲熟女精品中文字幕| 一区二区三区乱码不卡18| 免费黄频网站在线观看国产| 一级片免费观看大全| 欧美另类一区| 欧美成人午夜精品| 高清视频免费观看一区二区| 性少妇av在线| 水蜜桃什么品种好| 捣出白浆h1v1| 99热网站在线观看| 少妇 在线观看| 欧美人与善性xxx| 少妇被粗大猛烈的视频| 久久午夜福利片| 精品亚洲成a人片在线观看| 肉色欧美久久久久久久蜜桃| www.熟女人妻精品国产| 自线自在国产av| 国产男女超爽视频在线观看| xxx大片免费视频| 亚洲欧美中文字幕日韩二区| 久久久久精品人妻al黑| 日本vs欧美在线观看视频| 最近手机中文字幕大全| 18+在线观看网站| 黄片无遮挡物在线观看| 一级毛片我不卡| 欧美日韩亚洲高清精品| 黄频高清免费视频| www.精华液| 秋霞在线观看毛片| 大陆偷拍与自拍| 亚洲成国产人片在线观看| 免费日韩欧美在线观看| 精品视频人人做人人爽| 婷婷色综合大香蕉| 一本大道久久a久久精品| 欧美97在线视频| 日韩av在线免费看完整版不卡| 国产精品一区二区在线不卡| 欧美成人午夜免费资源| 伊人亚洲综合成人网| 国产精品女同一区二区软件| 国产深夜福利视频在线观看| 母亲3免费完整高清在线观看 | 日韩欧美一区视频在线观看| 日本午夜av视频| 中文字幕av电影在线播放| 新久久久久国产一级毛片| 永久免费av网站大全| 国产精品一区二区在线不卡| 自线自在国产av| 成年美女黄网站色视频大全免费| 精品少妇久久久久久888优播| 国产爽快片一区二区三区| 在线天堂最新版资源| 成年女人毛片免费观看观看9 | 欧美黄色片欧美黄色片| 少妇的丰满在线观看| 日韩 亚洲 欧美在线| 欧美黄色片欧美黄色片| 日韩制服骚丝袜av| 亚洲欧美精品综合一区二区三区 | 欧美另类一区| 亚洲国产精品国产精品| 纵有疾风起免费观看全集完整版| 日本爱情动作片www.在线观看| 自线自在国产av| 高清黄色对白视频在线免费看| 久久午夜综合久久蜜桃| 国产欧美日韩一区二区三区在线| 亚洲第一区二区三区不卡| 97在线视频观看| 久久久久久人人人人人| 亚洲av欧美aⅴ国产| 久久综合国产亚洲精品| 在线观看一区二区三区激情| 两性夫妻黄色片| 咕卡用的链子| 国产又色又爽无遮挡免| 最近最新中文字幕免费大全7| 人妻少妇偷人精品九色| 黑丝袜美女国产一区| 熟女少妇亚洲综合色aaa.| 三级国产精品片| 色94色欧美一区二区| 亚洲av福利一区| 在线观看www视频免费| 亚洲经典国产精华液单| 中文字幕最新亚洲高清| av在线app专区| 麻豆av在线久日| 免费观看无遮挡的男女| 考比视频在线观看| 18禁裸乳无遮挡动漫免费视频| 麻豆乱淫一区二区| 肉色欧美久久久久久久蜜桃| 高清不卡的av网站| 国产成人午夜福利电影在线观看| 国产麻豆69| 丝袜脚勾引网站| 精品人妻熟女毛片av久久网站| 七月丁香在线播放| 老汉色∧v一级毛片| 欧美激情高清一区二区三区 | 亚洲精品在线美女| 最近最新中文字幕大全免费视频 | 国产视频首页在线观看| 国产精品久久久av美女十八| 哪个播放器可以免费观看大片| 最近手机中文字幕大全| 亚洲精品美女久久久久99蜜臀 | 欧美日韩精品成人综合77777| 国语对白做爰xxxⅹ性视频网站| 1024香蕉在线观看| 国产亚洲欧美精品永久| 欧美亚洲日本最大视频资源| 成人毛片a级毛片在线播放| 黄片播放在线免费| 午夜影院在线不卡| 日本wwww免费看| 97人妻天天添夜夜摸| 亚洲久久久国产精品| 日韩中文字幕视频在线看片| 韩国精品一区二区三区| 男人操女人黄网站| 韩国av在线不卡| 90打野战视频偷拍视频| 极品人妻少妇av视频| 色播在线永久视频| 国产xxxxx性猛交| 在线免费观看不下载黄p国产| 蜜桃国产av成人99| 欧美日韩综合久久久久久| 日韩三级伦理在线观看| 日日摸夜夜添夜夜爱| 中文字幕亚洲精品专区| 久久精品人人爽人人爽视色| 亚洲国产欧美在线一区| 国产片特级美女逼逼视频| 久久精品熟女亚洲av麻豆精品| 国产 一区精品| 亚洲 欧美一区二区三区| 日日啪夜夜爽| 精品人妻偷拍中文字幕| 久久综合国产亚洲精品| 国产深夜福利视频在线观看| 午夜福利在线观看免费完整高清在| 欧美国产精品一级二级三级| 亚洲欧美清纯卡通| 国产淫语在线视频| 男女边摸边吃奶| 国产视频首页在线观看| 另类精品久久| 18禁国产床啪视频网站| 天天操日日干夜夜撸| 一区二区三区乱码不卡18| 亚洲国产毛片av蜜桃av| 国产伦理片在线播放av一区| 日本-黄色视频高清免费观看| 日产精品乱码卡一卡2卡三| www.精华液| 777久久人妻少妇嫩草av网站| 99久久人妻综合| 国产一区二区激情短视频 | 亚洲美女视频黄频| 少妇熟女欧美另类| 人成视频在线观看免费观看| 99九九在线精品视频| 尾随美女入室| 黑人猛操日本美女一级片| videos熟女内射| 日本色播在线视频| 丰满饥渴人妻一区二区三| 狠狠婷婷综合久久久久久88av| xxxhd国产人妻xxx| 久久久精品免费免费高清| 久久久精品国产亚洲av高清涩受| 在线亚洲精品国产二区图片欧美| 欧美精品一区二区免费开放| 亚洲欧美一区二区三区国产| 最近最新中文字幕大全免费视频 | 亚洲精品久久午夜乱码| 国产毛片在线视频| av一本久久久久| 丝袜喷水一区| 国产成人91sexporn| 亚洲成人一二三区av| 91午夜精品亚洲一区二区三区| 日韩欧美精品免费久久| 大陆偷拍与自拍| 国精品久久久久久国模美| 18+在线观看网站| 自拍欧美九色日韩亚洲蝌蚪91| 免费黄网站久久成人精品| 久久99精品国语久久久| 国产精品国产三级国产专区5o| 亚洲av日韩在线播放| 热re99久久国产66热| 国产探花极品一区二区| 黑人欧美特级aaaaaa片| kizo精华| 国产片内射在线| 男人添女人高潮全过程视频| 中文精品一卡2卡3卡4更新| 久久精品国产亚洲av天美| 免费高清在线观看视频在线观看| 亚洲欧美精品综合一区二区三区 | 好男人视频免费观看在线| 不卡视频在线观看欧美| 最近中文字幕高清免费大全6| 国产av一区二区精品久久| 亚洲一级一片aⅴ在线观看| 韩国精品一区二区三区| 久久这里只有精品19| 久久久久久久大尺度免费视频| 国产黄色免费在线视频| 日韩一区二区三区影片| freevideosex欧美| 少妇人妻精品综合一区二区| 美女大奶头黄色视频| 国产精品熟女久久久久浪| 最近中文字幕2019免费版| 亚洲色图综合在线观看| 老汉色av国产亚洲站长工具| 我的亚洲天堂| 欧美日本中文国产一区发布| 午夜免费鲁丝| 久久国产精品男人的天堂亚洲| 精品人妻偷拍中文字幕| 久久精品夜色国产| 日韩av不卡免费在线播放| 亚洲精品日本国产第一区| 香蕉丝袜av| 精品卡一卡二卡四卡免费| 亚洲中文av在线| 天美传媒精品一区二区| 国产一区二区三区综合在线观看| 天美传媒精品一区二区| 捣出白浆h1v1| 久久 成人 亚洲| 看免费成人av毛片| 国产成人免费无遮挡视频| 亚洲,欧美,日韩| 国产一区二区 视频在线| 国产不卡av网站在线观看| 国产成人精品婷婷| 日韩一区二区视频免费看| 日韩中文字幕视频在线看片| 日韩视频在线欧美| 又粗又硬又长又爽又黄的视频| 亚洲国产毛片av蜜桃av| 国产成人精品婷婷| 日韩精品免费视频一区二区三区| 夫妻午夜视频| 少妇被粗大的猛进出69影院| 免费av中文字幕在线| 免费少妇av软件| av又黄又爽大尺度在线免费看| 天天躁狠狠躁夜夜躁狠狠躁| 亚洲综合色网址| 91成人精品电影| 中文字幕人妻熟女乱码| 如何舔出高潮| 欧美bdsm另类| 自线自在国产av| 亚洲美女视频黄频| 日本91视频免费播放| 99久久中文字幕三级久久日本| 久久久久久人妻| 免费在线观看黄色视频的| 在线亚洲精品国产二区图片欧美| 亚洲欧美成人综合另类久久久| 男人舔女人的私密视频| 极品人妻少妇av视频| 伊人久久国产一区二区| 国产成人免费观看mmmm| 久久国产精品男人的天堂亚洲| 777米奇影视久久| 久久久国产欧美日韩av| 又粗又硬又长又爽又黄的视频| 青春草视频在线免费观看| 一边亲一边摸免费视频| 蜜桃在线观看..| 97在线视频观看| 赤兔流量卡办理| 成人影院久久| 久久av网站| 日本av手机在线免费观看| 国产一区二区三区综合在线观看| av卡一久久| 国产男女超爽视频在线观看| 欧美 亚洲 国产 日韩一| 丝袜美腿诱惑在线| 99久久精品国产国产毛片| 丝袜美腿诱惑在线| 美女国产高潮福利片在线看| 母亲3免费完整高清在线观看 | 国产男女超爽视频在线观看| 久久国内精品自在自线图片| 国产成人精品无人区| 国产精品久久久久久精品电影小说| 男的添女的下面高潮视频| 人妻少妇偷人精品九色| 在线观看免费日韩欧美大片| 久久精品久久久久久久性| 成人黄色视频免费在线看| 欧美 日韩 精品 国产| 欧美日韩精品成人综合77777| 欧美日韩亚洲高清精品| 国产精品秋霞免费鲁丝片| 午夜精品国产一区二区电影| 国产97色在线日韩免费| 久久国产精品男人的天堂亚洲| 欧美精品国产亚洲| 少妇的逼水好多| av天堂久久9| 人妻 亚洲 视频| 亚洲欧洲日产国产| 亚洲国产精品999| 久久人人爽av亚洲精品天堂| 岛国毛片在线播放| av国产久精品久网站免费入址| 中文字幕另类日韩欧美亚洲嫩草| 2021少妇久久久久久久久久久| 欧美xxⅹ黑人| 韩国av在线不卡| 亚洲熟女精品中文字幕| 精品亚洲乱码少妇综合久久| 少妇的丰满在线观看| 成年女人在线观看亚洲视频| 亚洲av免费高清在线观看| 永久免费av网站大全| 亚洲精品成人av观看孕妇| 在线观看免费日韩欧美大片| 国产爽快片一区二区三区| 桃花免费在线播放| 一区二区日韩欧美中文字幕| 观看美女的网站| 欧美激情极品国产一区二区三区| 一本久久精品| 欧美精品人与动牲交sv欧美| 国产精品一二三区在线看| 国产精品无大码| 亚洲美女搞黄在线观看| 啦啦啦在线观看免费高清www| 亚洲人成网站在线观看播放| 成人影院久久| 久久精品国产亚洲av涩爱| 91精品伊人久久大香线蕉| 你懂的网址亚洲精品在线观看| 亚洲一区中文字幕在线| 欧美亚洲 丝袜 人妻 在线| 免费看av在线观看网站| 亚洲综合色惰| 国产精品香港三级国产av潘金莲 | 可以免费在线观看a视频的电影网站 | 亚洲国产成人一精品久久久| 成人国产av品久久久| 成人免费观看视频高清| 99久久精品国产国产毛片| 一级,二级,三级黄色视频| 蜜桃国产av成人99| 色吧在线观看| 久久久精品免费免费高清| 观看美女的网站| 亚洲成人av在线免费| 欧美国产精品va在线观看不卡| 婷婷色麻豆天堂久久| 18禁动态无遮挡网站| 日韩大片免费观看网站| 两个人免费观看高清视频| 久久久久久久精品精品| 亚洲成人av在线免费| 国产精品久久久久久精品电影小说| 只有这里有精品99| 精品亚洲乱码少妇综合久久| 国产亚洲午夜精品一区二区久久| 亚洲国产日韩一区二区| 99久国产av精品国产电影| 日产精品乱码卡一卡2卡三| 成年av动漫网址| 中文精品一卡2卡3卡4更新| 亚洲,欧美精品.| 丝袜美足系列| 美女大奶头黄色视频| 欧美亚洲日本最大视频资源| 爱豆传媒免费全集在线观看| 亚洲,欧美精品.| 午夜日韩欧美国产| 亚洲av欧美aⅴ国产| 蜜桃国产av成人99| 爱豆传媒免费全集在线观看| 欧美黄色片欧美黄色片| 天天躁日日躁夜夜躁夜夜| 精品福利永久在线观看| 欧美日韩亚洲高清精品| 亚洲av福利一区| 亚洲成av片中文字幕在线观看 | 久久久久国产网址| 日本欧美国产在线视频| 国产精品无大码| 国产亚洲精品第一综合不卡| 国产亚洲最大av| 黄色一级大片看看| 在现免费观看毛片| 一区在线观看完整版| tube8黄色片| 久久热在线av| 精品国产乱码久久久久久男人| 久久精品夜色国产| 国产麻豆69| 两个人免费观看高清视频| 久久 成人 亚洲| 纵有疾风起免费观看全集完整版| 欧美 日韩 精品 国产| 久久久久国产一级毛片高清牌| 亚洲第一青青草原| 久久午夜福利片| 麻豆av在线久日| 丝瓜视频免费看黄片| 国产精品欧美亚洲77777| 日本黄色日本黄色录像| 国产精品久久久久成人av| 汤姆久久久久久久影院中文字幕| 亚洲少妇的诱惑av| 国产精品一区二区在线不卡| 精品国产一区二区三区久久久樱花| 亚洲精品第二区| 国产一区二区在线观看av| 亚洲人成网站在线观看播放| 久久午夜福利片| 亚洲av中文av极速乱| 男人舔女人的私密视频| 国产精品欧美亚洲77777| 亚洲中文av在线| 777久久人妻少妇嫩草av网站| 国产欧美日韩综合在线一区二区| 精品视频人人做人人爽| 在线观看免费高清a一片| 日韩人妻精品一区2区三区| 久久久久久久国产电影| 欧美国产精品一级二级三级| 久久精品人人爽人人爽视色| 亚洲精品第二区| 99热网站在线观看| 久久av网站| 免费在线观看视频国产中文字幕亚洲 | 免费日韩欧美在线观看| 日本午夜av视频| 久久精品熟女亚洲av麻豆精品| 黄色毛片三级朝国网站| 一级,二级,三级黄色视频| 亚洲国产精品国产精品| 两个人看的免费小视频| 在线天堂最新版资源| 亚洲成人一二三区av| xxx大片免费视频| 国产欧美亚洲国产| 日韩 亚洲 欧美在线| 亚洲伊人久久精品综合| 久久av网站| 免费日韩欧美在线观看| 99热国产这里只有精品6| 久久久精品免费免费高清| 午夜日韩欧美国产| 免费人妻精品一区二区三区视频| 一个人免费看片子| 欧美日韩视频高清一区二区三区二| 肉色欧美久久久久久久蜜桃| 欧美成人精品欧美一级黄| 有码 亚洲区| 亚洲人成77777在线视频| 亚洲五月色婷婷综合| 色吧在线观看| 日本黄色日本黄色录像| 97人妻天天添夜夜摸| 性少妇av在线| 在线精品无人区一区二区三| 国产老妇伦熟女老妇高清| 国产欧美日韩综合在线一区二区| 久久毛片免费看一区二区三区| av电影中文网址| 免费观看a级毛片全部| 男人添女人高潮全过程视频| 国产精品久久久久久av不卡| 亚洲av国产av综合av卡| 少妇精品久久久久久久| 精品少妇久久久久久888优播| av网站免费在线观看视频| 韩国精品一区二区三区| 久久热在线av| 亚洲精品aⅴ在线观看| 亚洲精品一区蜜桃| 国产日韩一区二区三区精品不卡| 久久精品国产亚洲av高清一级| 国产爽快片一区二区三区| 制服人妻中文乱码| 美女脱内裤让男人舔精品视频| 欧美亚洲日本最大视频资源| 多毛熟女@视频| 一级毛片黄色毛片免费观看视频| 晚上一个人看的免费电影| 久久久精品94久久精品| 精品人妻熟女毛片av久久网站| 亚洲欧美一区二区三区久久| 久久久久久久久久久久大奶| 国产成人免费无遮挡视频| 丝袜喷水一区| 国产精品 欧美亚洲| 99国产精品免费福利视频| 久久国内精品自在自线图片| 亚洲欧美成人精品一区二区| 精品少妇内射三级| 亚洲激情五月婷婷啪啪| 欧美 亚洲 国产 日韩一| 国产精品无大码|